Executive Summary
A single massive $817M HHS delivery order to IPG DXTRA, INC. highlights robust federal demand for health insurance exchange outreach via advertising, with $770M already outlayed providing immediate revenue visibility through 2027. This Time & Materials contract under full competition signals strength in government comms services, though long duration exposes to fiscal risks.
Investors gain a high-confidence bullish entry on IPG DXTRA and NAICS 541810 peers amid concentrated HHS spending.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior All HHS Contracts digest from March 08, 2026.
Investment Signals (1)
- $817M HHS Order Secures Multi-Year Revenue (HIGH)▲
IPG DXTRA's $816.9M obligation (77% outlayed) for health exchange education extends to March 2027, bolstering ad agency cash flows.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Time & Materials structure vulnerable to audits on labor rates and costs.
- Market [HIGH RISK]▼
Long performance to 2027-03-10 risks budget cuts or program shifts.
Opportunities (1)
- ◆
$51M unexercised options plus $46.8M remaining obligation offer upside.
Sector Themes (1)
- ◆
Unusual concentration in one $817M ad contract signals sustained federal investment in public education amid insurance exchanges.
Watch List (1)
- 👁
{"entity"=>"IPG DXTRA, INC.", "reason"=>"Dominates period with 100% of $817M value; tracks HHS revenue concentration.", "trigger"=>"Outlays exceeding 90% or option pulls for buy/hold signals"}
Get daily alerts with 1 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: All HHS Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals